Abstract:Elder patients with non-small cell lung cancer (NSCLC) have been habitually underrepresented in clinical trails. Retrospective analysis have shown similar therapeutic outcome of platinum-based combined chemotherapy for fit elderly, albeit more toxicity compared with younger coun-terparts. Gefitinib, an oral EGFR-TKI was generally well tolerated with clinically meaningful anti-tumor activity in previously treated patients as well as chemo-naïve patients. The aim of the study was to retrospectively evaluate the toxicity, efficacy and survival of gefitinib versus platinum-based combined chemotherapy as first-line treatment for a series of Chinese patients aged 70 and over with advanced NSCLC. from January 2002 to December 2005, 38 patients received chemotherapy (17 of Novelbine, 8 of Gemcitabine, 7 of taxol and 7 of taxotere, all of which combined with cisplatin or carboplatin) and 17 patients received gefitinib 250mg once daily as first line treatment. Of the 38 patients who received chemotherapy, the median age was 73.3 years old (70-80) with 68.4% male, 73.7% adenocarcinoma and 78.9% patients were in stage 4. The PS of all patients was 0-1. Of the 17 patients who received gefitinib, the median age was 76.9 years old (70-85) with 58.8% male, 64.7% adenocarcinoma and 82.4% patients were in stage 4. The PS of 6 patients was over 2. The most frequently reported adverse events for chemotherapy group were neutropenia (92.1%) and thrombocytopenia(73.7%). Grade 3/4 neutropenia was 21.1% and four patients had nertropenia febril. Grade 3/4 thrombocytopenia was 10.5% and 2 patients need blood transfusion. Other grade 3/4 adverse effects included 3 cases of vomiting and one case of cardiac arrhythmia. 4 patients withdrew the chemotherapy due to side effects. The most frequently reported adverse events for gefitinib group were skin disorders (70.6%) and diarrhea (35.3%). The majority of these events were mild with grade 1 to grade 2. One patient was hospitalization due to grade 3 diarrhea and recovered without drug administration disruption. Other adverse events included 2 cases of nausea, 1 case of oral ulcer and 1 case of elevation in hepatic enzymes. No patient withdrew due to adverse effect. The par-tial response and disease control rate were 21.1% and 78.9% for chemotherapy group versus 17.6% and 68.8% for gefitinib group. The median progress free survival and overall survival time were 4.93 ± 0.747 months (95% CI: 3.465, 7.395) and 13.882 ± 0.718 months (95% CI: 12.892, 20.708) for chemotherapy group versus 6.4 ± 1.852 months (95%CI: 2.770, 10.030) and 15.882 ± 2.029 months (95%CI: 13.654, 20.505). The one-year survival was 52.6% in chemotherapy group versus 47.1% in gefitinib group. There is no statisti-cal significance between the two groups for efficacy, progress free survival time and overall survival time. Platinum-based combined chemotherapy was well tolerated and provides significant anti-tumor activity in elder patients. Gefitinib as first-line treatment provides similar clinical benefit with less toxicity for the elder NSCLC patients.

Doublet Versus SINGLE Cytotoxic Agent As First-Line Treatment for Elderly Patients with Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

Efficacy of Pemetrexed Plus Platinum Doublet Chemotherapy As First-Line Treatment for Advanced Nonsquamous Non-Small-cell-lung Cancer: a Systematic Review and Meta-Analysis.

Comparing Single‐agent with Doublet Chemotherapy in First‐line Treatment of Advanced Non‐small Cell Lung Cancer with Performance Status 2: A Meta‐analysis

Comparing single-agent with doublet chemotherapy in first-line treatment of advanced non-small cell lung cancer with performance status 2: A meta-analysis.

A research of platinum-based dual drugs versus single agent chemotherapy for elderly and comorbidity patients with advanced non-small cell lung cancer

A Meta-Analysis of Combination Therapy Versus Single-Agent Therapy in Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer: Results from Nine Randomized Phase III Trials

Doublet vs Single-Agent Maintenance Therapy in the Treatment of Non-Small-Cell Lung Cancer: A Meta-Analysis

Meta-Analysis to Assess the Efficacy and Toxicity of Docetaxel-Based Doublet Compared with Docetaxel Alone for Patients with Advanced NSCLC Who Failed First-Line Treatment

Vinorelbine versus vinorelbine-carboplatin in treatment of elderly patients with advanced non-small cell lung cancer

Oxaliplatin-Based Doublets Versus Cisplatin or Carboplatin-Based Doublets in the First-Line Treatment of Advanced Nonsmall Cell Lung Cancer

New Agent Triplet versus Doublet Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer:a Systematic Review

Comparison of Single-Agent Chemotherapy and Targeted Therapy to First-Line Treatment in Patients Aged 80 Years and Older with Advanced Non-Small-cell Lung Cancer

The Efficacy and Safety of Pemetrexed-Based Doublet Therapy Compared to Pemetrexed Alone for the Second-Line Treatment of Advanced Non-Small-cell Lung Cancer: an Updated Meta-Analysis

Treatment of Elderly Patients or Patients Who Are Performance Status 2 (PS2) with Advanced Non-Small Cell Lung Cancer Without Epidermal Growth Factor Receptor ( EGFR ) Mutations and Anaplastic Lymphoma Kinase ( ALK ) Translocations – Still a Daily Challenge

[A Randomized Clinical Trial on the Clinical Efficacy and Toxicities of Single-Agent Paclitaxel Liposome Versus Paclitaxel Liposome Plus Oxaliplatin As First-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer in Elderly Patients].

P2-325: Chemotherapy in elderly (Over 75 years old)lung cancer patients: a retrospective analysis

Clinical Observation of Single-agent Docetaxel and Docetaxel Combined with Carboplatin in Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer

P3-163: Gefitinib versus chemotherapy as first-line treatment in elder patients with advanced non-small-cell lung cancer

Clinical Effectiveness and Clinical Toxicity Associated with Platinum-Based Doublets in the First-Line Setting for Advanced Non-Squamous Non-Small Cell Lung Cancer in Chinese Patients: a Retrospective Cohort Study.

Comparison Between Doublet Agents Versus Single Agent in Metastatic Breast Cancer Patients Previously Treated with an Anthracycline and a Taxane: a Meta-Analysis of Four Phase III Trials.

A Comparison Between Triplet and Doublet Chemotherapy in Improving the Survival of Patients with Advanced Gastric Cancer: a Systematic Review and Meta-Analysis